Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
January 23, 2025 07:00 ET
|
Vigil Neuroscience, Inc.
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and...
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
January 08, 2025 16:05 ET
|
Vigil Neuroscience, Inc.
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating...
Vigil Neuroscience to Present at Upcoming Investor Conferences
November 12, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease...
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
November 05, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
September 17, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
September 16, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Upcoming September Investor Conferences
August 29, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval...